Related Experiment Video
Updated: Jun 10, 2025
05:46
Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
1.7K
Plaque Radiotherapy for Ocular Melanoma.
George Naveen Thomas1,2, I-Ling Chou1,2,3, Lingam Gopal1,2
1Department of Ophthalmology, National University Health System, Singapore 119228, Singapore.
Cancers
|October 16, 2024
Summary
Ophthalmic plaque brachytherapy effectively treats medium-sized ocular tumors like uveal melanoma. Radioisotope choice and plaque customization ensure precise radiation delivery, with outcomes influenced by tumor characteristics.
Area of Science:
- Ophthalmology
- Radiation Oncology
- Medical Physics
Background:
- Ocular tumors, particularly uveal melanoma, require effective treatment strategies.
- Plaque brachytherapy is an established modality for medium-sized ocular tumors.
Purpose of the Study:
- To review and summarize the current state of ophthalmic plaque brachytherapy.
- To discuss radioisotope selection, treatment customization, and efficacy for uveal melanoma.
Main Methods:
- Literature review of ophthalmic plaque brachytherapy.
- Analysis of radioisotope choices (Ruthenium-106, Iodine-125, Yttrium-90, Ytterbium-169, Selenium-75).
- Evaluation of factors influencing treatment outcomes and complications.
Main Results:
- Plaque brachytherapy offers precise radiation delivery, customizable by plaque design and seed placement.
- Ruthenium-106 brachytherapy shows variable local control rates (59.0%-98.0%) for uveal melanoma.
- Tumor size, thickness, location, and apex dose impact efficacy and complication rates.
Conclusions:
- Ophthalmic plaque brachytherapy is effective for selected ocular tumors, including uveal melanoma, yielding survival rates comparable to enucleation for medium-sized tumors.
- Complications are well-documented and often treatable.
- Radioisotope selection depends on treatment duration, tumor specifics, and side effect profiles.
